Viridian Therapeutics, Inc./DE
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|
| Revenue | $8.4M | $4.0M | $3.5M | $5.7M | $6.5M | $5.5M |
| Cost of Revenue | — | — | $2.5M | $2.5M | $3.4M | $2.8M |
| Gross Profit | — | — | $929.0K | $3.2M | $3.1M | $2.7M |
| Gross Margin | — | — | 26.7% | 56.7% | 48.1% | 49.4% |
| Operating Expenses | ||||||
| Research & Development | $30.4M | $19.6M | $13.7M | $1.0M | $347.0K | $225.0K |
| SG&A Expense | $11.0M | $10.9M | $6.8M | $7.7M | $6.9M | $1.4M |
| Operating Income | $-33.1M | $-26.5M | $-17.0M | $-11.2M | $-6.9M | $-197.0K |
| Operating Margin | -394.5% | -662.8% | -488.6% | -196.1% | -105.9% | -3.6% |
| Interest Expense | — | — | $95.0K | $141.0K | $1.0M | $2.0M |
| Pretax Income | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | $0 | $0 | — |
| Net Income | $-32.7M | $-26.5M | $-17.3M | $-11.3M | $-7.9M | $-2.2M |
| Net Margin | -390.0% | -662.3% | -496.8% | -198.5% | -121.7% | -39.3% |
| EPS (Basic) | $-0.12 | $-0.15 | $-3.13 | $-2.34 | $-0.39 | $-1.36 |
| EPS (Diluted) | $-0.12 | $-0.15 | $-3.13 | $-2.34 | $-0.39 | $-1.36 |
| Shares Outstanding (Basic) | 277.6M | 203.1M | 7.5M | 6.4M | 34.0M | 0 |
| Shares Outstanding (Diluted) | 277.6M | 203.1M | 7.5M | 6.4M | 34.0M | 0 |
| Dividends Per Share | — | — | — | — | — | — |